What does Lin BioScience, Inc. do?

Lin BioScience, Inc. (6696.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6696.TWO's market cap?

Lin BioScience, Inc. (6696.TWO) has a market capitalization of approximately $77.86 billion, as of August 19, 2026, based on the most recent share price and shares outstanding.

Does 6696.TWO pay a dividend?

No — Lin BioScience, Inc. (6696.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6696.TWO profitable?

Lin BioScience, Inc. (6696.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6696.TWO

Lin BioScience, Inc.

TWO·Biotechnology · Healthcare

NT$939.00NT$0.00+0.00%

Market capNT$77.86B·Market closed·Aug 19 6:59 AM UTC

Price Chart

NT$939.00+NT$0.00 (+0.00%)today

+590.85%CAGR +47.20%

Select date range

FromTo

Oct 8, 2018Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6696.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateAug 13

Last Report DateAug 12

Reported vs Estimate−NT$1.05

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$0.00

Net Income−NT$1.92B

Net Margin—

Operating Cash Flow−NT$1.85B

Capital ExpendituresNT$26.09M

Free Cash Flow−NT$1.87B

Return on Equity−18.1%

Return on Invested Capital−8.9%

Net CashNT$16.50B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6696.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6696.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6696.TWO and 80,000+ other tickers.

About Lin BioScience, Inc.

Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and…

CEO: Zhengqi Wang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 20
Website: www.linbioscience.com

Peers

Pell Bio-Med Technology Co., Ltd.

Cap

NT$97.7B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6696.TWO

What does Lin BioScience, Inc. do?: Lin BioScience, Inc. (6696.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6696.TWO's market cap?: Lin BioScience, Inc. (6696.TWO) has a market capitalization of approximately $77.86 billion, as of August 19, 2026, based on the most recent share price and shares outstanding.
Does 6696.TWO pay a dividend?: No — Lin BioScience, Inc. (6696.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6696.TWO profitable?: Lin BioScience, Inc. (6696.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.